MODIFIED PTC/SB/08 (08-00)
Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

numper.						
	Substitute fo	r form 1449B	/PTO		Complete if Known	OPE
	INFORMATI	ON DISCLO	SURE	Application Number	09/897,755	4
	STATEMEN			Filing Date	07/03/2001	
				First Named Inventor	Peng Cho TANG	MR 2 6 2004 i
				Group Art Unit	1626	Mar C. a man G
	(use as many s	heels as ne	cessary)	Examiner Name	Sonya N. Wright	3
Sheet	1	of	1	Attomey Docket Number	034536-0107	70 000

Examiner Initiats*	Cite Foreign Patent D No.1 Office3 Number4		ocument Kind Code ³ (il known)	. Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	70	
K-5	A1	EP	0 252 713	81	PFIZER INC.	09-12-1990		<u> </u>
								/

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	7
ics	A2	DESIMONI et al., "Catalysis with Inorganic Cations. V.1 Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium Perchlorate on Chemoselectivity," <u>Tetrahedron</u> , 1996, pp. 1200-12018. Vol. 52, No. 36, Elsevier Science Ltd.	
Ks	А3	GIBSON et al., "Cleavage of Haiogenobenzophenones by Potassamide in Ammonia; New Routes to Xanthem- and Thioxanthen-9-ones," <u>J.C.S. Perkin I</u> , 1975, pp. 155-160	
Ks	A4	KULKA et al., "I-Butyl as a Blocking Group in the Synthesis of o-Hydroxybenzophenones," November 5, 1954, pp. 5469-5471	
-			

Examiner Signature	Kamal	Sneed	Date Considered	03/03/04
-----------------------	-------	-------	--------------------	----------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any commants on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

UST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		-					_							1				
AC S 3 9 7 7 8 7 200/299 1200/299 14 14 15 2 10 6 1 10 200/299 14 10 10 10 10 10 10 10	FORM P	TO-1	449							1,11		ATTY, DUCKET NO.		1				
Peng Cho Tang et al. Filing Date	usi	OF P	AJENI	IS AP	1D O	THE	RITE	MS F	OR A	PPLICANTS					צט	, 07	. , , , , ,	······
FILING DATE		25	-							rfúi 🏅 .	:		ang	et 2	.		•	
MAR 3 : 200 2 0 8 5 5 7 01/17/61 Burgard et al.	0		-XV:	se sev	reral :	sheet	s if n	ecess	aryi	•				-				
DOCLAMPST NUMBER DOCLAMPST NUMBER DATE NUMBER CLASS SAUE CLASS	MAR	3 ; 200														,	•	
DOCLAMPST NUMBER DATE NUMBER CLASS SUB CLASS CLASS NUMBER NUMBER NUMBER NUMBER NUMBER CLASS SUB CLASS	2		S									7/3/01				1621	9	<u>·</u> _
DOCUMENT MAMBRE DATE NAME CASS CASS CASS CASS CASS NAME CASS CAS	N/E	TRACEN							Ų.S	. PATENT D	OCUM	ENTS						خادببيندي
AA 2 9 6 8 5 5 7 01/1761 Burgard et al. AB 5 4 0 9 9 9 4 9 04/95 Buzzesi et al. AC 5 3 9 7 7 8 7 8 7 03/14/95 Buzzesi et al. AD 5 3 7 4 6 5 2 12/20/94 Buzzesi et al. AE 5 1 2 4 3 4 7 06/22/92 Correct al. AF 5 3 3 0 9 9 9 2 07/1994 Graevat et al. AF 5 3 3 0 0 9 9 2 07/1994 Graevat et al. AG 5 4 6 3 0 5 2 10/31/95 Hags et al. AH 2 8 7 2 3 7 2 03/03/95 Hall AH 5 2 0 6 8 3 0 4 09/1989 Luruck et al. AK 5 3 8 8 2 5 9 3 0/99 Luruck et al. AK 5 3 8 8 2 5 9 3 0/99 United al. AK 5 2 1 7 9 9 9 9 06/08/93 Luruck et al. AK 5 2 1 7 9 9 9 9 06/08/93 Luruck et al. AK 6 4 2 3 0 9 02/10/87 Michel et al. AK 6 8 8 4 7 05/02/89 Michel et al. AK 6 8 8 4 7 05/02/89 Michel et al. AK 7 06/02/89 Michel et al. AK 8 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8					DOCUM	ABAT N	(LIMBE	R		DATE		NAME	1	245				_
AB 5 4 0 9 9 4 9 0495 Buzzeti et al. AC 5 3 9 7 7 8 7 8 7 09/1495 Buzzeti et al. AD 5 3 7 4 6 6 5 2 12/2094 Buzzeti et al. AE 5 1 2 4 3 4 7 06/2492 Correct et al. AF 5 3 3 0 9 9 9 2 07/1994 Escenta et al. AG 5 4 6 3 0 5 2 1031/85 Hags et al. AH 2 8 7 2 3 7 2 00/0999 Huli AI 5 2 0 6 2 6 1 0493 Kavaguchi et al. AI 5 2 1 7 9 9 9 9 06/0899 Levited al. AI 5 2 1 7 9 9 9 9 06/0899 Levited al. AI 6 6 4 2 3 0 9 02/1088 Michel et al. AN 4 8 6 8 4 7 05/0889 Michel et al. AN 4 8 2 6 8 4 7 05/0889 Michel et al. AN 4 8 2 6 8 4 7 05/0889 Michel et al. AN 4 8 7 9 7 1 9 9 9 6 11/2090 Shirabhi et al. AN 4 8 7 9 7 1 9 9 6 11/2090 Shirabhi et al. AR 5 2 0 2 3 4 1 0439 Shirabhi et al. AR 5 3 0 8 9 5 1 6 00/1892 Shirabhi et al. AR 5 5 0 8 9 5 1 6 00/1892 Shirabhi et al. AN 5 3 0 8 9 5 1 6 00/1892 Shirabhi et al. AN 5 3 0 8 9 5 1 6 00/1892 Shirabhi et al.			╁		Γ.	1	T .	,	,	010781	-		╁		+		+-	
AC S 3 9 7 7 8 7 60/1495 Buzseti et al. AD S 3 7 4 6 5 2 122094 Buzseti et al. AE S 1 2 4 3 4 7 06/2492 Cornor et al. AF S 3 3 0 9 9 2 2 07/1994 Essensiat et al. AG S 4 6 3 0 5 2 10/3195 Hags et al. AH 2 8 7 2 3 7 2 02/03/99 Hull AN 5 2 0 6 2 6 1 04/93 Kanaguchi et al. AN 4 8 6 8 3 0 4 09/1989 Larock et al. AK 5 3 8 2 5 9 3 04/95 Le-Ruld AK 5 3 8 2 5 9 3 04/95 Le-Ruld AM 4 6 4 2 3 0 9 02/1087 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AN 4 8 5 0 5 1 4 1 7 09/24/91 Nadler et al. AN 4 8 5 3 4 0 3 08/03/99 Shirashi et al. AN 4 8 5 3 4 0 3 08/03/99 Shirashi et al. AN 4 8 5 3 4 0 3 08/03/99 Shirashi et al. AN 5 5 0 8 9 5 1 6 00/18/92 Shirashi et al. AN 5 5 0 8 9 5 1 6 00/18/92 Shirashi et al. AN 5 5 0 8 9 5 1 6 00/18/92 Shirashi et al.	7		┽╌╌	 		┝	-		_		- 		+	1	+-	1	╁	
AD S 3 7 4 6 5 2 12/2094 Buzzeti et al. AE 5 1 2 4 3 4 7 06/22/92 Correct al. AF 5 3 3 3 0 9 9 9 2 07/1994 Essensiate al. AG 5 4 6 3 0 5 2 10/31/85 Hage et al. AH 2 8 7 2 3 7 2 00/03/99 Half AN 5 2 0 6 2 6 1 04/33 Kawagachi et al. AN 4 8 6 8 3 0 4 09/19/89 Larack et al. AK 5 3 8 2 5 9 3 01/95 te Bau AL 5 2 1 7 9 9 9 9 0608/93 Lavade AM 4 6 4 2 3 0 9 02/10/87 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AN 4 8 5 3 4 0 3 08/04/89 Shirakhi et al. AN 4 8 5 3 4 0 3 08/04/89 Shirakhi et al. AR 5 2 0 2 3 4 1 04/393 Shirakhi et al. AR 5 3 0 5 7 5 3 8 10/15/91 Shirakhi et al. AN 5 3 0 2 6 0 6 0 6 04/12/94 Spotke et al.	-1-		+-	├	 	 	 		<u> </u>		 		╁	+	╫	1-	╁╌	
AE 5 1 2 4 3 4 7 O6/26/92 Correct et al. AF 5 3 3 0 9 9 2 07/19/94 Essentate et al. AG 5 4 6 3 0 5 5 2 10/31/95 Hage et al. AH 2 8 7 2 3 7 2 00/09/99 Hall AI 5 2 0 6 2 6 1 04/93 Kavagachi et al. AK 5 3 8 2 5 9 3 04/95 Levick et al. AK 5 3 8 2 5 9 3 04/95 Levick et al. AA 4 6 4 2 3 0 9 06/08/99 Levick et al. AA 4 6 4 2 3 0 9 02/10/87 Michel et al. AA 4 6 4 2 3 0 9 02/10/87 Michel et al. AA 4 8 5 0 5 1 4 1 7 09/94/91 Nacher et al. AA 4 8 5 0 5 1 4 1 7 09/94/91 Nacher et al. AA 5 5 0 5 7 5 3 8 10/15/91 Shirakhi et al. AA 5 5 0 8 9 5 1 6 02/18/92 Shirakhi et al. AA 5 5 0 8 9 5 1 6 02/18/92 Shirakhi et al. AA 5 5 0 8 9 5 1 6 02/18/92 Shirakhi et al. AA 5 5 0 8 9 5 1 6 02/18/92 Shirakhi et al.			+	 	 	┢┷	 						+	+	╁	\vdash	+-	
AF 5 3 3 0 9 9 2 07/1994 Essentated al. AG 5 4 6 3 0 5 2 1031/35 Haga et al. AH 2 8 7 2 3 7 2 0003/39 Hall AH 5 2 0 6 2 6 1 0493 Kanaguchi et al. AN 4 8 6 8 3 0 4 09/1989 Laruck et al. AK 5 3 8 2 5 9 3 01/35 Ler Baut AK 5 2 1 7 9 9 9 9 0608/93 Lervicki AM 4 6 4 2 3 0 9 02/1087 Michel et al. AN 4 8 2 6 8 4 7 0500/89 Michel et al. AN 4 8 2 6 8 4 7 0500/89 Michel et al. AN 4 8 7 0 5 0 5 1 4 1 7 09/4/91 Nacibre et al. AP 4 9 7 1 9 9 9 6 11/2090 Shirakhi et al. AP 4 9 7 1 9 9 6 11/2090 Shirakhi et al. AR 5 2 0 2 3 4 1 04/3/93 Shirakhi et al. AR 5 2 0 2 3 4 1 04/3/93 Shirakhi et al. AR 5 3 0 5 7 5 3 8 10/15/91 Shirakhi et al. AN 5 3 0 5 7 5 3 8 10/15/91 Shirakhi et al. AN 5 3 0 5 7 5 3 8 10/15/91 Shirakhi et al.			+	3	┢┷	 	-		- -				+	+		 	+	
AG S 4 6 3 0 5 2 1031/26 Haga et al.		-	+	1	 	-	 	 					┿	+	┩╌	-	+-	
AH 2 8 7 2 3 7 2 0000/59 Hull AN 5 2 0 6 2 6 1 0493 Kanaguchi et al. AN 4 8 6 8 3 0 4 090/989 Latuk et al. AK 5 3 8 2 5 9 3 0145 Le Baut AK 5 2 1 7 9 9 9 9 060893 Levizid AM 4 6 4 2 3 0 9 02/1087 Michel et al. AN 4 8 2 6 8 4 7 0500/89 Michel et al. AN 4 8 2 6 8 4 7 0500/89 Michel et al. AN 4 9 7 1 9 9 6 11/2090 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AR 5 0 5 7 5 3 8 100/591 Shiraishi et al. AN 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AN 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AN 5 3 0 8 9 5 1 6 02/18/92 Shiraishi et al.			}	3	3	 	-		-		-		+	+	+-	-	+	
A1 5 2 0 6 2 6 1 0493 Kanaguchi et al. A3 4 8 6 8 3 0 4 091989 Larock et al. AK 5 3 8 2 5 9 3 0145 Le Bau AK 5 2 1 7 9 9 9 9 060093 Leviddi AM 4 6 4 2 3 0 9 021087 Michel et al. AN 4 8 2 6 8 4 7 0660289 Michel et al. AN 4 8 2 6 8 4 7 0660289 Michel et al. AN 4 9 7 1 9 9 6 1172090 Shirakhi et al. AP 4 9 7 1 9 9 6 1172090 Shirakhi et al. AR 5 2 0 2 3 4 1 041393 Shirakhi et al. AR 5 3 0 8 9 5 1 6 021892 Shirakhi et al. AX 5 3 0 8 9 5 1 6 021892 Shirakhi et al. AX 5 3 0 8 9 5 1 6 021892 Shirakhi et al. AX 5 3 0 8 9 5 1 6 021892 Shirakhi et al. AX 5 3 0 8 9 5 1 6 021892 Shirakhi et al. AX 5 3 0 8 9 5 1 6 021892 Shirakhi et al.		∕ C	5	4	6	3	0	5	2		 		╀	4		ļ	4	····-
AK 5 3 8 2 5 9 3 01/95 Levizld AK 5 3 8 2 5 9 3 01/95 Levizld AK 5 2 1 7 9 9 9 9 06/08/93 Levizld AM 4 6 4 2 3 0 9 02/1087 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AN 4 9 7 1 9 9 6 11/20/90 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AN 5 3 0 8 9 5 1 6 02/18/92 Shiraishi et al. AN 5 3 0 8 9 5 1 6 02/18/92 Shiraishi et al. AN 5 3 0 8 9 5 1 6 02/18/92 Shiraishi et al.		AH	2	8.	7	2	3	7	2	02/03/59	HA		╀-	4	 			
AK 5 3 8 2 5 9 3 01/95 Le Baut AL 5 2 1 7 9 9 9 9 06/08/93 Levitald AM 4 6 4 2 3 0 9 02/10/87 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AO 5 0 5 1 4 1 7 09/24/91 Nadler et al. AP 4 9 7 1 9 9 6 11/20/90 Shiraishi et al. AQ 4 8 5 3 4 0 3 08/01/89 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AV 5 3 0 2 6 0 6 04/12/94 Spacka et al.	-	N	5	2	0	6	2	6	1	0493	Kaw	agushi et al.	\bot	4			┦	
AL 5 2 1 7 9 9 9 9 060893 Levizdi AM 4 6 4 2 3 0 9 02h087 Michel et al. AN 4 8 2 6 8 4 7 050289 Michel et al. AO 5 0 5 1 4 1 7 09/2491 Nadler et al. AP 4 9 7 1 9 9 6 11/2090 Shiraishi et al. AQ 4 8 5 3 4 0 3 08/0189 Shiraishi et al. AR 5 2 0 2 3 4 1 04/1393 Shiraishi et al. AS 5 0 5 7 5 3 8 10/1591 Shiraishi et al. AT 5 0 8 9 5 1 6 02/1892 Shiraishi et al. AV 5 3 0 2 6 0 6 04/1294 Spacka et al.		N	1	8	6	8	3	0	4	09/19/89	Laru	keak	_	4	1_		4_	
AMA 4 6 4 2 3 0 9 02/1087 Michel et al. AN 4 8 2 6 8 4 7 05/02/89 Michel et al. AO 5 0 5 1 4 1 7 09/24/91 Naciler et al. AP 4 9 7 1 9 9 6 11/20/90 Shirashi et al. AQ 4 8 5 3 4 0 3 08/01/89 Shirashi et al. AR 5 2 0 2 3 4 1 04/13/93 Shirashi et al. AS 5 0 5 7 5 3 8 10/15/91 Shirashi et al. AV 5 3 2 2 9 5 0 06/94 Sicar et al. AV 5 3 0 2 6 0 6 04/12/94 Spada et al.		٨K	5	3	8	2	5	9	3	01/95	te B	a.i.	\bot	1	╄.		_	
AN 4 8 2 6 8 4 7 0500/89 Michel et al. AO 5 0 5 1 4 1 7 09/24/91 Naciler et al. AP 4 9 7 1 9 9 6 11/20/90 Shiraishi et al. AQ 4 8 5 3 4 0 3 08/01/89 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 00/18/92 Shiraishi et al. AV 5 3 0 2 6 0 6 04/12/94 Sparka et al.		ÄL	5	2	1	7	9	9	9	06/08/93	levi	aki	_	1	_	<u> </u>	- 	
AO 5 0 5 1 4 1 7 09/24/91 Naciler et al. AP 4 9 7 1 9 9 6 11/20/90 Shiraishi et al. AQ 4 8 5 3 .4 0 3 08/01/89 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Sircar et al. AV 5 3 0 2 6 0 6 04/12/94 Sparks et al.	·	м	4	6	4	2	3	0	9	02/10/87	Mid	र्थ सं भे	_		1_	<u> </u>	\perp	
AP 4 9 7 1 9 9 6 11/20/90 Shiraishi et al. AQ 4 8 5 3 4 0 3 08/01/89 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Siccar et al. AV 5 3 0 2 6 0 6 04/12/94 Spacka et al.		₹	4	8	2	6	8	4	7	05/02/89	Mid	र्व स क्षे		\perp				
AQ 4 8 5 3 4 0 3 08/01/89 Shiraishi et al. AR 5 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Sircar et al. AV 5 3 0 2 6 0 6 04/12/94 Spacka et al.		8	5	0	5	1	4	1	7	09/24/91	Nad	er et al.	$oldsymbol{\perp}$	L	L			
AR S 2 0 2 3 4 1 04/13/93 Shiraishi et al. AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Sircar et al. AV 5 3 0 2 6 0 6 04/12/94 Spacka et al.		٨P	4	9	7	1	9.	9	6	11/20/90	Shira	क्षेत्रं स ब्रं					_	
AS 5 0 5 7 5 3 8 10/15/91 Shiraishi et al. AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Sircar et al. AV 5 3 0 2 6 0 6 04/12/94 Sparka et al.		Ą	4	В	5	3	.4	0	3	08/01/89	Shira	ishi et al.						
AT 5 0 8 9 5 1 6 02/18/92 Shiraishi et al. AU 5 3 2 2 9 5 0 06/94 Sincar et al. AV 5 3 0 2 6 0 6 04/12/94 Spacks et al.	-	AR	5	2	0	2	3	4	1	04/13/93	Shira	ક્રીમાં લ એ.					$\cdot $	
AU 5 3 2 2 9 5 0 06/94 Sircar et al. AV 5 3 0 2 6 0 6 04/12/94 Spacks et al.		AS	5	0	5	7	5	3	8	10/15/91	Shira	ishi et al.						
AV 5 3 0 2 6 0 6 04/12/94 Spards et al.		AT	5	0	8	9	5	1	6	02/18/92	Shira	ishi et al						
		ΑÙ	5	3	2	2	9	5	0	06/94	Sirca	r et al.						
LS AW 4 9 6 6 8 4 9 10/30/90 Vallee et al.		AV	5	3	٥	. 2	6	0	6	04/12/94	Spad	ક લ સ		1		1		
	Es	AW	4	9	6	6	8	4	9	10/30/90	Valle	ट हर ही.	-		1-	-		
1																		
FORBIGN PATENT DOCUMENTS		·	·				<u></u> -		FOR	BCN PATENT	DOCU	ABNTS.			·			
EXAMPLER DOCUMENT NUMBER DATE COUNTRY CASS SUB TRANSLATION	-			D	OCUM	ent M	JAJEER.			CATE		COUNTRY	a	ASS				
Mattrue									-				-			_		NO

								FOR	BCN FATEN	L DOCTIMBALE				
DOWNER									0.7	CO10/TTV	0.48	SUB	TRANS	MOTA
INITIAL	<u> </u>			<u> </u>	<u> </u>	UMES			CATE	COUNTRY	CLASS.	ava	YE5	NO
Ks	AX	0	5	6	6	2	6	6	15.1.93	EPO (Barker et al.)	_	57		1
105	AY	9	4	1	4	8	0	8	07.07.94	WOPCT (Buzzett et al.)		ا		
K	AZ	G	5	2	5	4	7	. 2	03.02.93	EO क्रिक्टलां न्द्र सी		7;7;7 - 0		
1cs	BA	9	5	0	1	3	4.	9	12.01.95	WOPCT (Buzzeni et al.)		,	-	
RS	88	9	6	1	6	9	6	4	06.06.96	WOPCT (Buzzetti et al.)		17-3		
ES	BC	0	6	6	2	4	7	3	12,07.95	EPO (Buzzeti et al.)		-	٠.	

EXAMINER Kamal Saced	DATE CONSIDERED: 09/03/04
	0 01 03/07

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line the citation if not in conformance and not considered. Include a copy of this form with next communication to applicate

						٠ <u>٠</u> ٠								
FORM PTO-14	149				'n,					ATTY. DE T NO		ŞE	RIAL NO).
			in o	TITE	D ATT	F	~ ~ .			38602-1220 ''09/897,755				
LIST OF PA	ORM	ATIC)N D		OSU	RE ST		APPLICANT: Peng Cho Tang et al.						
MAR 0 1 2002	3								FILING DATE: GROUP: 16276					
THE PRINTERANT	- -						U.S	. PATENT DO	CUME	NTS				
EXAMINER PRITIAL			ocu	MENT I	A LIMEE	R		DATE		NAME	Q.A	×	CYZ	FILING DATE
_														
						·								

		_			_			fO	RECN PATEN	T DOCUMENTS				
EXAMINER				****		. M M.//DI	10		DATE	COUNTRY	CLASS	SUB	TRANSLATION	
INITIAL		DOCUMENT NUMBER							COATA	uxs	CAS	YES	NO	
KS	M	0	6	2	6	3	7	7	11/30/94	EPO (Haga et al.)	-			
•	AB	9	7	3	6	8	6	7	10/09/97	WOPCT (Howard)				
$\cdot $	¥.	9	2	8	6	7	7	7	11/04/97	Japan			_	
7	8	9	5	1	4	6	6	7	06/01/95	WOPCT (Masarnune)				
	Æ	3	3	1	0	8	9	1	09/27/84	Cemany (Michel et al.)				
	AF	3	4	2	6	4	1	9	01/23/86	Cermany (Michel et al.)				
	AG	9	7	2	5	9	8	6	07/24/97	WOPCT (Sato et al.)				
4-5	АН	٥	7	8	8	8	9	0	08/13/97	EPO (Vanneele)		_		

•		OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)
ks	AI	Howard, Provisional Patent Application No. 60/015,134 filed March 29, 1996 for "Lactam Derivatives"
<u> </u>	-	
		P S O
•		TEN 1500/250

EXAMINER:	DATE CONSIDERED:
	i

^{*}MINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORA	4 81	r0.1	440				_				ATTY. DULKET NO. SERIAL NO.	
•											38602/1220 -09/897,755	· ·
U	ISŢ (OF PA INF	TENT: ORM/	S AN ATIO	D O	THER SCLO	. ITEA XSUR	as fo E ST/	YK AI	ent / ·	APPLICANT:	
_	(P										Peng Cho Tang et al.	
/0) ' '	- 4	e (Us	e sev	etai 1	inecu	i ji ne	cess.	ary)		FILING DATE: GROUP:	
(H	AR O	1 2002	1								7/3/01 1625	
لِيُّةٍ السَّالِيَّةِ السَّالِيَّةِ السَّالِيَّةِ السَّالِيَّةِ السَّالِيَّةِ السَّالِيِّةِ السَّالِي			S S									
1200	S TR	ADEMA	<i>"</i>									
125		80	9	6	0	0	2	2	6	04.01.96	WOPCT (Buzzeti et al.)	
1		BE	9	5	1	7	1	8	1	29.06.95	WOPCT (Buzzerd et al.)	
1		BF	9	1	1	3	0	5	5	05.09.92	WOPCT (Buzzetti et al.)	
		8 C	9	3	0	1	1	8	2	21.01.93	WOPCT (Buzzeti et al.)	
		ВН	9	4	0	3	4	2	7	17.02.94	WOPCT (Dathain et al.)	
		81	9	72	2	1	6	6	Ó	10.04.92	WOPCT (Dow)	
	一	BJ.	9	1	1	5	4	9	S	17.10.91	WOPCT (Dow et al.)	
	寸	BK	0	5.	8	0	5	0	.2	01.94	EPO .	
	\exists	BL		8	7	8	5	3	9	06.53	Септалу	
	1	BM	2	6	8	9	3	9	7	08.10.93	France (Guillaume et al.)	
	寸	BN		8	٥	9	6	9	1	04.93.59	Creat Britian (Hull)	
	十	во	1	3	9	В	2	2	. 4	29.03.65	France (Imperial Chemical)	
	_	BP BP	6	2	2	9	5	7	0	07.02.87	Japan	
	寸	BQ	6	2	3	9	5	6	4	02.87	japan	
	寸	BR	ಟ	1	4	1	9	5	5	14.06.88	Japan	
	+	BS	9	4	1	0	2	0	2	11.05.94	WOPCT (christon et al.)	
	十	81	·	2	8	6	8	7	0	04.12.64	Australia (Murnane and Moore)	
	十	BU	0	3	5	1	2	1	3	17.01.90	EPO (Nadler et al.)	
	十	ВV	9	2		7	8	3	0	14,05.92	WORCT (Nationish) et al.)	
	十	BW	0	6	3	2	7	9	2	15.06.94	EPO (Roschger)	
	十	8X	•	5	5	8	8	9	4	09.03.93	Japan (Sakuda et al.)	
-	\dashv	BY	. 2	,	1	2	6	3	4	20.09.91	Carrecta (Satian)	
	-	82	2	7	5	9	3	6	0	14.06.73	Germany Scheer et al.)	
	-	3	2	1	5	9	3	6	7	1406.73	Cermany (Scheer et al.)	
	\dashv	8	2	1	5	9	3	6	2	1406.73	Cermany Scheer et al.)	
	\dashv	8	2	1	5	9	3	6	3	14.06.73	Centrarry (Scheer et al.)	
	\dashv		- -	8	3	5	4	7	3	18.05.60	Great Britain Senior)	•••
	\dashv	8		8	0	7	0	3	5	22,09,88	WOPCT Shiralshi et al.)	
	-	Œ	8	├─	 		7		1	06.05.92	WOPCT Spaces et al.)	
-		Œ ~~	9	2	0	3	-	3	6	15.11.73	Cermany (Torniarson)	
		8	2	3	2	1	6	5	6	19.02.75		
<u> </u>		<u> </u>	1	3	8	4	5	9	9		Great Britian (Tornlinson)	
#		O	9	6	2	2	9	7	6	08/96	WORCT	<u> </u>
			-	\vdash	-	-	-	_	-		 	
 				-	-	-	-	-	-	 	 	
		•			<u>L</u> .		1		<u> </u>			

EXAMINER:	Kamal Saced	DATE CONSIDERED:	08/03/	04

EXAMINER: Initial II reference is considered, whether or not citation is in conformance with MPEP 609; Drav citation if not in conformance and not considered. Include a copy of this form with next communication to

FORM PTO-1449	ATTY. DÜÜKET NO. 38602-1220	SERIAL NO. 09/897,755	
LIST OF PATENTS AND OTHER ITEMS FOR APRICANT'S INFORMATION DISCLOSURE STATEMENT O P E (Use several sheets if necessary)	APPLICANT: Peng Cho Tang	CENTER 06	
MAR 0 ; 7807 &	FILING DATE: - 7/3/01	CROUPS - 25	VED

- O TR	ADEMA	
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
FS	Cl	Abramovitch et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," Chemistry and Industry 44:1871 (1967)
	CK	Abramovitch and Hey, "Internuclear cyclisation," I. Chem. Soc. pp. 1697-1703 (1954)
	CL	Akbasak and Suner-Akbasak et-al., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)
	СМ	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. I. Med. Chem.</u> 25:187-190 (1990)
	CN	Andreani et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," Eur. J. Med. Chem. 28:653-657 (1993)
	co	Andreani et al., "Synthesis of lacatams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)
,	CP	Andreani et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. I. Med. Chem.</u> 27:167-170 (1992)
	cq	Arteaga et al., "Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice," <u>I. Clin. Invest</u> , 84:1418-1423 (1989)
	CR	Autrey and Tahk, "The Synthesis and Sterochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967)
	CS	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," <u>I. Med. Chem.</u> 12:721-722 (1969)
	ст	Bamfield et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>I. Chem. Soc. (C)</u> pp. 1028-1030 (1966)
	S	Baserga, "Oncogenes and the strategy of growth factors," Cell 79:927-930 (1994)
•	CY	Baserga, "The insulin-like grwoth factor I receptor: a key to tumor growth?" Cancer Res. 55:249-252 (1995)
	CW	Blake and Jaques, "Anisotropic Effects in alpha-substituted methoxystilbenes," <u>J. Chem. Soc. Perkin</u> <u>II</u> pp. 1660-1663 (1973)
	α	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB</u> <u>1.</u> 6:3403-3409 (1992)
	٦.	Bolen, "Nonreceptor tyrosine protein kinases," Oncogene 8:2025-2031 (1993)
	cz	Borsche et al., "Uber nielkernige kondersierte systeme mit heterocyclischen ringen," <u>Liebigs Ann.</u> <u>Chem.</u> 550:160-174 (1941)
·	DA	Buzzetti et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)
	· DB .	Canoira and Rodriguez, "Synthesis of Oxindole Derivatives from N-Alkenyl-o-Chloroanilides with Zero-Valent Nickel Complex," <u>I. Heterocyclic Chem.</u> 22:1511-1518 (1985)
	DC	Chatten et al., "Substituted Oxindoles. Part VI. Polargraphic Reduction of Substituted trans-3-benzylideneindol-2(3H)-ones," <u>I. Chem. Soc. Perkin II</u> pp. 469-473 (1973)
	DD	Coda et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>L. Chem. Soc. Perkin 11</u> pp. 615-619 (1984)
Ks	DE	Coppola et al., "A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor," Mol. Cell. Biol. 14:4588-4595 (1994)
<u> </u>		(10074)

EXAMINER:	tamal saced.	DATE CONSIDERED: 08/03/04
	Famai Sacco.	00/00/07

EXAMINER: Initial II reference is considered, whether or not citation is in conformance with MPEP 609; Draw line the citation if not in conformance and not considered. Include a copy of this form with next communication to applica.

FORM PTO-1449	ATTY, DUCKET NO. 38602/1220	SERIAL NO; 09/897,755 -
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT OF E COMPANY OUTPER TEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT OF E COMPANY OF E C	APPLICANT: Peng Cho Tang et	
MAR D : TOTT	FILING DATE: 7/3/01' "	GROUP: 3 - 5 [

indol-2(3H)-
ast cancer cells,"
Growth Factor,"
lactate factor (TNF)
east cancer,"
xindoles by -
fic Molecules
er the Human or 0:1550-1558
owth Factor -858 (1989)
tics (5th
ritro and in
of the National
Expression
nic Mice: A :311-314 (1988)
hem. Soc.
Canadian I.
s Protein-
y by Genetic
<i>H</i> - 92)
of Oxindole

EXAMINER:	Kamal	saced	DATE CONSIDERED:	0.8/00	104

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449	ATTY. DOCKET NO. 38602-1220	SERIAL NO. 09/897,755_
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT O P E (Use several sheets if necessary)	APPLICANT: Peng Cho Tang et al.	
MAR 8 ZMZ E	FILING DATE: 7/3/01	. GROUP:

	PHADE	
K	EA	fellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994)
1	EB	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)
	EC	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble-receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)
	ED	Khalil and Abdel-Rahman, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>I. Indian Chem. Soc.</u> 54:904-907 (1977)
	EE	Kim et al., "Inhibition of vascular endothelial growth factor-induced anglogenesis suppresses tumour growth in vivo," <u>Nature</u> 362:841-844 (1993)
	EF	Kinselia et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Exp. Cell Research 199:52-62 (1992)
	EG	Klagsbrun and Soker, "VEGF/VPF: the angiogenesis factor found?" Current Biology 3:699-702 (1993)
	EH	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97(9):1033-1039 (1977)
	El	Koch et al., "5H2 and 5H3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)
	Ej	Korc et al., "Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concumitant increases in the levels of epidermal growth factor and transforming growth factor alpha," <u>I. Clin. invest.</u> 90:1352-1360 (1992)
	EX	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity", " L. Immunol. Methods 64:313-320 (1983)
	FL	Kovac and Stetinova, "Furan derivatives LXXX. Synthesis and properties of substituted furfurylidenoxindoles," <u>Chem. tvesu</u> 30:484-492 (1976)
	EM	Kumbas et al., "Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," Oncosene 7:627-633 (1992)
	ĖN	Larock and Babu, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:52991-5294 (1987)
	EO	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>I. Cell. Biol.</u> , 118:1057-1070 (1992)
	EP	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Res.</u> 50:2511-2517 (1990)
	EQ	Mariani et al., "inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)
	ER	Martin-Lean et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring," Liebigs Ann. Chem. pp. 101-104 (1990)
	ES	Mirand et al., "A Synthetic Entry in the Aristotelia Alkalolds," I. Ork. Chem. 47:4169-4170 (1982)
	£T	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," L. Immunol. Methods 65:55-63 (1983)
KS	EU	Neber and Rocker, "Ueber die einwirkung voon benzaldehyden auf die freie o-aminophenyi- essigsaure," <u>Chem. Ber.</u> 56:1710-1717 (1923)

EXAMINER:	Kamal	Saced	DATE CONSIDERED:	08/03/04

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 600; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449	ATTY. DÚCKET NO. 38602-1220	SERIAL NO. ☐ 09/897,75€ ☐
UST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Peng Cho Tang	NICH 160 S 0 6 20 S 0 6 20
MAR 8 1 MIN E	FILING DATE: 7/3/01	CROUPS - 2 - 11

Ks	£V	Nodiff et al., "Antimalarial Phenanthrene Amino Aicohols. 1. Fluorine-Containing 3- and 6- Substituted 9-Phenanthrenemethanols," <u>I. Med. Chem.</u> 14:921-925 (1971)
)	EW	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'- Dialitylaminoisoindogenides," Clinica Chimica Acta 62:181-182 (1975)
	EX	Osborne et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)
	£Y	Ozzello and Sordat, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)
	EZ.	Pavlenko et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr. R\$B</u> 7:64-66 (1980)
	FA	Plate, "Vascular endothelial growth factor is potential tumor anglogenesis factor in human gilomas in vivo," Nature 359:845-848 (1992)
	FB	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)
	FC	Ruveda and Gonzalez, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)
,	fO	Rygaard and Povisen, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice." <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)
	FE	Sandberg-Nordqvist et al., "Characterization of insulin-like growth factor 1 in human primary brain tumors," Cancer Res. 53:2475-2478 (1993)
	FF	Schindler et al., "Über Dibenzib,ff-azocin-Derivate," Helvetica Chimica Acta 49:985-989 (1966)
	fG	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," Neuron 9:383-391 (1992)
	FH	Schnierle et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," Liebigs Ann. Chem. 715:90-97 (1968)
	FI	Schuchter et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," Cancer Research 51:682-687 (1991)
	FJ	Selbert et al., "Clonal Variation of MCF-7 Breast Cancer Cells In Vitro and In Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)
	FK	Shafie and Grantham, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," 1. Natl Cancer Institute 67(1):51-56 (1981)
	FL	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely realted to the fms family," Oncozene 5:519-524 (1990)
	FM	Shiraishi, "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," Biochemical and Bionhysical Research Communications 147:322-328 (1987)
	FN	Shiraishi et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4- Hydroxycinnamamide Derivatives in Vitro," <u>Cancer Research</u> 49:2374-2378 (1989)
	FO	Shweiki, "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," Nature 359:843-845 (1992)
	FP	Skehan et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl.</u> <u>Cancer Inst.</u> 82:1107-1112 (1990)
Ks	FQ	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)

EXAMINER	Kamal	soled	DATE CONSIDERED:	0-8	103/04
					5 tr t

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw fine through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

			-73
FORM PTO-1449	ATTY. DOCKET NO. 38602-1220	SERIAL NO.	(EC
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT O 1 P E (Uso several sheets if necessary)	APPLICANT: Peng Cho Tang et	318	EIVE
MUR B, ZOTE SE	FILING DATE: 7/3/01	GROUPS N	Ö
MADEMARK			

	E MAN	
·Ks	FR	Songyang et al., "Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/les, GR8-2, HCP, SHC, Syk and Vav," Molecular and Cellular Biology 14:2777-2785 (1994)
\	F5	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," Cell 72:767-778 (1993)
	អ	Stetinova et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection</u> <u>Czechoslov. Chem. Commun.</u> 42:2201-2206 (1976)
	fU	Sumpter and Milier, "Chapter IV - Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , Interscience Publishers, Inc., New York, pp. 134-153 (1954)
	FV	Tacconi et al., "(Z)- and (£)-3-Alkylidene-1,3-dihydroIndol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," I.C.S. Perkin II pp. 150-154 (1976)
	FW	Tacconi and Marinone, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)
	FX	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," Mol. Bio. Cell 4:358A (1993)
	FY	Thompson et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>1. Chem. Soc. Perkin</u> <u>Trans. (1)</u> pp. 1835-1837 (1993)
	FZ	Torp et al., "Expression of the epidermal growth factor receptor gene in human brain metastases," <u>AMPIS</u> 100:713-719 (1992)
	GA	Triebs et al., "Uber Isolndigolde Farbstroffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> 702:112-130 (1967)
	GB	Tuzl et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)
	GC	Ultrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990)
	GD	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Grwoth Factor," <u>I. Biol.</u> <u>Chem.</u> 265:19461-19466 (1990)
	GE	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>1. Indian Chem. Soc.</u> 66:804-805 (1989)
	CF	Voller et al., "Enzyme-Linked Immunosorbent Assay," In Manual of Clinical Immunology, 2nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)
	GG	van Dabeneck et al., "a.8'-Diindolylmethane und -methene. Der Urorosein-Chromophor," Zur Chemie des Indols VI:1347-1357 (1969)
	GH	Wahl et al., "Chimie Organique - Sur les iso-indogenides," C.R. Hebd. Seancest Acad. Sci., 149:132-134 (July 1909)
	GI	Walker, "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(B-Alkylaminoethyl)-2-indolinones. The Reduction of Isolandogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>I. Med. Chem.</u> 8(5):626-637 (1965)
	GJ	Walker, "Synthesis of a a-(p-Aminophenyl)- and a-(p-Chlorophenyl)-B-aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," I. Med. Chem. 8(5):583-588 (1965)
	GK	Warri et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-I Human Breast Cancer Cells In Vitro and in Nude Mice," Int. I. Cancer 49:616-623 (1991)
. 15	GL	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," New England 1, Medicine 324:1-7 (1991)

EXAMINER:	Kamal	Suced	DATE CONSIDERED:	08/03/04
EXAMINER: In	nitial if reference is consi	dered, whether or not citation is	in conformance with MP	EP 609: Draw line through

.

سعا سسمت أسار فنجيب عا	والمستوان المتحدد المتحدد المتحدد والمتحدد والمتحد والمتحد والمتحد والمتحد والمتحدد والمتحدد والمتحدد والمتحدد والمتحدد والمتحدد				
FORM PTO-144	[1]	ATTY. DUCKET NO. 38602-1220	SERIA ÉNO. 09/897,755€		
O17E	NTS AND OTHER ITEMS FOR APPLICANT'S MATION DISCLOSURE STATEMENT '	APPLICANT: Peng Cho Tang et al.			
MAR 0 1 2002	8	FILING DATE:	GROUP: 1		
ALTER ST		7/3/01	162		
CS CM	Winkelmann et al., "Chemotherapeutical D," ArznelmForsch/Drug Res. 27(1):22:	ly Active Nitro Compounds: 4	. S-Nitrolmidazoles (Part		
ics GN	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," IACS 78:221-224 (1956)				
KS 60	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDI, 27032." J. Cellular Physiology 152:448-457 (1992)				

Ks	GM	Winkelmann et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part D," <u>ArznelmForsch./Drug Res.</u> 27(II):2251-2263 (1977)
KS	GN	Wright et al., "Cyclic Hydroxamic Acids Derived from Indole," IACS 78:221-224 (1956)
KS	GO	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>I. Cellular Physiology</u> 152:448-457 (1992)
KS	GP	Young and Babbitt, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon Paste Electrode in Acidic Aqueous-Ethanolic Media," <u>I. Org. Chem.</u> 47:1571-1572 (1982)
KS	CQ	Zhungletu et al., "Reaction of Indoles and 2-Ketolndolines With Some Aldehydes," <u>Institute of</u> <u>Chemistry. Academy of Science of the Moldavian SSR, Kishiney pp. 34-37 translated from Khimiya Geterotsiklicheskikh Soedinenii</u> 1:40-44 (1973)

EXAMINER: Carrel Soveed DAYE CONSIDERED: 08/03/04

	•••				16.				
FORM PTO-1449				ATTY, DOCKET NO. SERIAL NO.					
نه و ه	T 05 04	TENITE ANID OTHER ITEM	IC EMP APPLICA	NTIC	38602-1220 . 09/897,755			MAR	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			144.3	APPLICANT:				≈	
· Ó	13E				Peng Cho Tang et al.			<u> </u>	
		(Use several sheets if ner	cessary)		FILING DATE:		GROUP:	7 E	200%
<u></u>		3	<u></u>		7/3/01		162	6 3	7
- 123		<u> </u>				 			<u>;</u>
	Dark W	<i>3</i> /	U.S. PAT	ENT DOC	UMENTS	 	1 41.00		ILING
EXAME		DOCUMENT NUMBER	DATE		NAME	CLASS	SUB		DATE
								1	
						}	 	-	
						<u> </u>			
			FOREIGN PA	ATENT DO	CUMENTS				
EXAMINE							SUB	TRANSL	ATION
DALTINE		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	CLASS	YES	NO
KS	A	WO 99/10325	04.03.99	PCT (A	AcNutt et al.)			•	
							·		
						<u>,i</u>	l		<u> </u>
		OTHER DOCUM	MENTS (Includin	g Author,	litle, Date, Pertinent P	ages, Etc.)			
1 -	γ	Andreani et al., "In \					olinanes	, •	
KS	AB	Arzneimittel-Forschi						••	
(-	Carpenedo et al., "lo					olinone)	in the	
	AC	Mammalian Brain a							
	 	Chen et al., "Effects							
	AD	Elicited Chloride Cu	1	-	_			_	
		40(3):149-156 (1997							
$\overline{\cdot}$		Damiani et al., "Inhil							
	AE	Quinoline and Indoli 1161 (1994)	none Nitroxid	e Radica	ils, <u>Biochemical I</u>	'narmacol	<u>ogy</u> 48(0	b):115;)-
	 	Davis et al. *Synther	ole and Micro	hiologica	Donnarios of 3.4	mino 1 H	vdrova 3	Indoli	2020
•	AF	and Related Compo							HUING
	1	Graziani et al., "Hep							18
	AG	Nucleotide Exchang							
		Kato et al., "Simulta						•	
	AH	Benzoyl-2-Oxindole		7	•	e Liquid C	hromato	graph	y."
		Journal of Chromato		<u>·</u>	<u> </u>				
		Maass et al., Viral I				•)T	:
	Al	Nonnucleoside Inhib Transcriptase," Anti-			•			9931	
 	┼	Moreto et al., "3,3-B				•			
•	LA	Metabolite of the La	xative Sulisat	in Arzn	eimittel-Forschung	Drug Re	search 2	29(II):1:	561-
		1564 (1979)							
		Moreto et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric					furic		
	AK	Diester of 3,3 Bls-(4	-Hydroxyphei	nyi)-7-M	ethyl-2-Indolinone				
	 	European Journal o				ial Assass	17	· Ibi	
	AL	Singh et al., "Indolin Mikrobiol, 144:105-		185 2\$ PC	itenual Antimicrob	iai Agenta	. <u>Lenira</u>	<u>(C)).</u>	
	 	Singh et al., "Synthe		onvulsa	nt Activity of New	1-Substitu	ted 1'-M	ethyl-3	•
Ks	AM	Chloro-2-Oxosprio (
133:76-79 (1994)									

EXAMINER: Komal Society	DATE CONSIDERED: 08/03/09
EXAMINER: Initial if reference is considered, whether or not citation is in citation if not in conformance and not considered. Include a copy of this	

FORM PTO-1449	ATTY. DOCKET NO.	SERIAL NO.	
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S	38602-1220	09/897,755	
OT . PROPREMATION DISCLOSURE STATEMENT	APPLICANT: Peng Cho Tang et al.		
HAR B 1 2002	FILING DATE: . 7/3/01	GROUP: 1627	

		Y
	PADLY	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
ts	AN	Soldl et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13(3):515-525 (1998)
KS	AO	Tsai et al., "The Effect of 3,3-Di-Pyridyl -Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," Neuomharmacology 31(9):943-947 (1992)
KS	AP	Zamen et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β-Receptor (β-PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999)
Y.S	AQ	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-294 (1996)

FIECEIVED

MAR 0 6 2002

TECH CENTER 1600/2900

EXAMINER: Kand Saced	DATE CONSIDERED: 0-2/03/04
EXAMINER: Initial if reference is considered, whether or ne citation if not in conformance and not considered. Include	at citation is in conformance with MPEP 609; Draw line through a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Peng	Cho	Tang	ci

FILING DATE 7-3-01

GROUP:

	U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS	CIASS	FILING S			
	AA			·						
	AB				·		~			
	AC		,							
	AD	•	·				,			
	AE						•			
	AF	·		•		:	•			
•	AG	•	• •							
	AH									
	AI	·								
•	AJ		·							
	AK			•		· [

FOREIGN PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER	UMENT NUMBER COUNTRY		CLASS	SUB	TRANSLATION			
<u>C8</u>	AL	WO 96/32380	10/17/96	WO/PCT (Battistini)	-	· .	YES	NO		
108	AM	WO 96/22976	08/01/96	WO/PCT (Buzzetti)		1	·			
KS	AN.	WO 96/40116	12/19/96	WO/PCT (Tang)		1				
	AO	•	•	. `						
	AP	•				·				

•		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
rs	AQ	Andreani et al., "Potential Antitumor Agents. 25[1]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolylmethlene) 1,3-Dihydroindol-2-Ones," AntiCancer Research 16:3585-3588 (1996)
	AR	Terrett et al., "Combinatorial Synthesis-The Design of Compound Libraries and their Application to Drug Discovery," Tetrahedron 51(30):8135-8173 (1995)
	AS .	Coda et al., "3-(4-methylbenzilidene)-1-,3-dihydroindol-2-one," Journal of the Chemical Society. Perkin Transactions 2 4:615-620 (1984), DATABASE CROSSFIRE, Beilstein No. 6-21
	AT .	Wahl, "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," Ann. Chim p. 350 (1926), DATABASE CROSSFIRE, Beilstein No. 2-21-00-00290
rs	AU ·	Elliot, "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," Journal of Organic Chemistry 29:2438-2440 (1964), DATABASE CROSSFIRE, Beilstein No. 5-24
	AV	

EXAMINER:	10 01 i		DATE CONSIDERED:	:21 -1 0
	Fumas	5		49 / 0/20

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEF 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449 ATTY. DOC SERIAL NO. 24 09/897,755 38602-1220 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S APPLICANT: INFORMATION DISCLOSURE STATEMENT Peng Cho Tang et al. (Use several sheets if necessary) GROUP FILING DATE 7-3-01. U.S. PATENT DOCUMENTS 2002 CLAMENER SU8 DOCUMENT NUMBER DATE NAME **GY22** INITIAL CLASS AA AB AC AD ΑE AF AG AH AI AJ AK FOREIGN PATENT DOCUMENTS TRANSLATION **EXAMINER** COUNTRY CLASS DOCUMENT NUMBER DATE INITIAL CÍVZZ NO 04/01/95 EPO (Roschger) AL 0 632 102 X WO 97/25986 WO/PCT (Sato) 07/24/97 AM AN AQ AP OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AQ AR AS AT

EXAMINER:	ramal	Soveed
		0000

DATE CONSIDERED: 09/03/04

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

	PRM PTO-1449.				ATTY. DOCKET NO. 38602-1220		SERIAL . 09/897.755				
LIŞT	INFO	ENTS AND OTHER ITEMS FOR RMATION DISCLOSURE STAT	EMENT	i	APPLICANT: Peng C. Tang et al.		, ,	•			
1	512	Else Averal sheets if necessar	y) 		FILING DATE: GROUP: 1627						
	(AS 0 1	1.				الرسوب المقالات			- 0-		
10	,	4 C1	U.S. PATENT D	OCU	MENTS .			γ			
EXAMINATE OF	R	DE NA POOCUMENT NUMBER	DATE		NAME	CASS	SUS		LING		
<u> </u>					· · · · · · · · · · · · · · · · · · ·		•				
· Jan							1	 			
			1			+-	†	+			
							-	 			
	 		+	<u> </u>				+-			
		 					-	+			
			 				-	+			
	·						┼				
			 				-	-}	•		
		•					-	—	 :		
			1		·						
		FC	DREIGN PATENT	1 000	CUMENTS				•		
YA MÍMEO			COUNTRY		SUB	TRANSLATION					
INITIAL		DOCUMENT NUMBER	DATE	}		CVZZ	CLASS	YES	NO		
15	· AA	1.398.224	29.03.65	Fra	nce				X		
	AB	Unknown	12.10.92	Hu	ngary				X		
						-	•				
الروسية الإرابات			<u> </u>	<u> </u>	<u> </u>			Ĺ	<u> </u>		
	- <u>-</u>	OTHER DOCUMENTS	Oncluding Auth	ar. Tit	ile, Date, Perlinent Page	s, Etc.)	<u> </u>				
	٠.]					·*			_		
5	AC	Bellstein Reg. No.: 25	2929 Beilstein								
								•			
					 			•	 -		
					······································						
											
			· · · · · · · · · · · · · · · · · · ·								
	-		·								
	-			<u> </u>	•						
					-						
							<u></u>				
EXAMINE	<u>.</u> /		a a id		DATE CONSIDERE	D: 🗼	1 -	1 1/	 1		
		comal 50		•	DATE CONSIDERE	U 7	1031	07			
EXAMINES citation is	l: Initial	if reference is considered, when interested is considered, when it is the considered in the considered	ether or not cita	tion is y of th	in conformance with M	PEP 609; C)raw line to applic	e throug ant.	gh		

HECEIVED

MAR 0 6 2002

TECH CENTER 1600/2900

FORM PT	O-1449					'Ț NO.	SERIAL N				
LIST	_	TENTS AND OTHER ITE DRMATION DISCLOSU		• • • •	38602-1220 09/897,755 APPLICANT: Peng Cho Tang et al.						
	OIP	Several sheets if n	ecessary)		FILING DAT		GROUP:	162%			
	MAR 0	1 2002		•							
12	3	- AND STATE OF THE PARTY OF THE	U.S. PA	TENT DOC	UMENTS	•		•			
EXAMINER INITIAL				NAME	CLASS	SUB CLASS	FILING DATE				
	ļ							·			
		ļ		· ·	•			-			
·				-	•		<u> </u>	<u> </u>			
·,-	· 			•			•				
		· · · · · · · · · · · · · · · · · · ·	FOREIGN	PATENT DO	CUMENTS						
NER INITIAL		DOCUMENT NUMBER	DATE	COU	NTRY	CLASS	SUB CLASS	TRANSLA- TION YES NO			
			-			1 65 65	CD 133	123 140			
				•							
			• •	•							
·		•					-				
			•	•							
		OTHER DOCUMEN	ITS (Includir	ng Author, Ti	tle, Date, Per	tinent Page	s, etc.)	<u>. </u>			
6s	AA	Andreani et al., "Sy imidazo [2,1-b] thi (1997)	nthesis and azolylmethy	potential co lene)-2-indo	anthracyclini linones," <u>Eur.</u>	c activity of I. Med. Ch	substitute em. 32:91	d 3-(5- 9-924			
	٠			•			ECH (χ _≤ Π			
·					•		ENTER	₹ C			
	•	· ·					1600	VE 200			
XAMINER:	Ka	emal sa	eed.	DATE	CONSIDERED	0 3/0)	/oy	Ö			
XAMINI	ER: Ini	tial if reference is cor	sidered, whe	ether or not ci	tation is in con	nformance w	ith MPEP	609; Draw			

communication to applicant

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE			ATTY. DOCKET NO.	SERIAL NO.					
(MODIFIED)		PATENT AND TRADEMARK OFFICE			038602-12	09/897,755					
	•	1			APPLICANT	20 at -1					
1 / 1 F F		ION DISCLOSURE	CITATION			ig-Cii	O TATA	GROUP ART UNIT 1620			
10.	CIEB				FILING DATE						
MAR 0 1 -200	// /bo ^	everal sheets if nece	ssary)		07/03/20	01		USPTO	ART	NITO1	
	M.I		U.S. PAT	Έλ	IT DOCUMENTS						
EXAMPLE DA	RE TO THE PERSON NAMED IN COLUMN TO	DOCUMENT					SUB-	FILI	NG DATE		
INITIAL	REF	NUMBER	DATE		NAME	C	LASS	CLASS	APPI	IF ROPRIATE	
	 -	5 899 MM	3/23/99		g et al.	+-					
- CS		5,886,020 5,792,783	 		g et al.	+		1	 		
1					<u> </u>		 	 	 		
	ļ	5,883,116			g et al.	-		+-+-	 		
		5,883,113			g et al.		-		 		
		5,880,141			g et al.	 			<u> </u>	<u></u>	
		5,409,903	4/25/95	Spa	da et al.	↓			ļ	· · · · · · · · · · · · · · · · · · ·	
		5,198,446	3/23/93	_ev	itzki Al		1		<u> </u>		
KS		5,322,590	6/21/94	Sirc	ar et al.	_					
			FOREIGN P	AT	ENT DOCUMENTS						
		DOCUMENT	DATE		COUNTRY		LASS	SUB-	TRANSLATION		
	REF	NUMBER DATE			COUNTRY		L-100	CLASS	YES	NO	
		· · · · · ·									
	<u> </u>	OTHER DOCU	MENTS (Includin	~ A	uthor, Title, Date, Pert	inent	Donne	Ftc 1	<u> </u>	•	
	1	OTHER DOCU	MEN 13 (MGBOM)	y ~			rayos,	£10.j			
CS		Carey, F.A. and Su 55-60; Plenum Pre		ctio	n and Synthesis," <u>Advan</u>	ced O	rganic C	hemistry. Pr	BIT B 3rd	edition:	
		Moreh I Advance	ed Ossania Chamist		4 th edition; 109-111 and	427 41	20: John	Millou R Co	•		
KS		wisich, J., Advance	ed Organic Chemisi	ту,	4 Polition; 109-111 and	127-14	30; Joni		ns		
ICS.		Gordon, E.M. et al. Synthesis, Library	, "Application of Co Screening Strategic	mb 85, 8	inatorial Technologies to and Future Directions," <u>J</u>	Drug Medi	Discove cinal Ch	ry. 2. Combi emistry 37:1	natorial 0, 1385	Organic 1401	
,								·			
EXAMINER	Kar	nal sac	red		DATE CONSIDER	ED (8/0	3/04			
1			-		er or not citation is not considered. In					-	
com	munica	tion to applicant.			······				220	ш	
								受	AR	\mathbf{C}	
								TEF	0	Ш	
							_	3 16	6 21	<	
I							•	CENTER 1600/2900	2002	EIVED	
002.737895								290	1	O	
								0	•		

Page 1 of 1

002.737895

Atty. Dkt. No. . . .

Page 1 of 1 SERIAL NO. U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. Form PTO-1449 PATENT AND TRADEMARK OFFICE 09/897,755 (MODIFIED) 38602-1220 APPLICANT OTP ENERRHATION DISCLOSURE CITATION Tang, et al. **GROUP ART UNIT** FILING DATE 162% MAR 0 1 2002 Huse several sheets if necessary) 7-3-01 U.S. PATENT DOCUMENTS FILING DATE DOCUMENT SUB-EXAMINER CLASS DATE NAME REF CLASS NUMBER INITIAL APPROPRIATE Apr 13, 1994 435 6 5,565,324 Oct. 15, 1996 Still, et al. **A1** 424 246 Sep 17, 1975 Oct 11, 1977 . Rovnyak, et al. 4,053,613 A2 Aug 12, 1975 . 4,002,749 Jan 11, 1977 Rovnyak 424 246 A3 **FOREIGN PATENT DOCUMENTS** TRANSLATION SUB-DOCUMENT **CLASS** COUNTRY - DATE REF **CLASS** NUMBER YES NO Feb 26, 1998 X WO 98 07695 A Europe OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.) 贸 1600/2900 DATE CONSIDERED EXAMINER Camal sneed EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.